# Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants

> **NCT03606746** · PHASE2 · WITHDRAWN · sponsor: **Medeor Therapeutics, Inc.**

## Conditions studied

- Kidney Transplant Rejection

## Interventions

- **BIOLOGICAL:** MDR-103

## Key facts

- **NCT ID:** NCT03606746
- **Lead sponsor:** Medeor Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12
- **Primary completion:** 2025-08
- **Final completion:** 2025-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03606746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03606746, "Cellular Immunotherapy for Immune Tolerance in Past Recipients of HLA Zero-mismatch, Living Donor Kidney Transplants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03606746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*